Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

Core Points - The Biotech Index (970038) closed at 2134.66 points, down 0.06%, with a trading volume of 13.045 billion yuan and a turnover rate of 0.95% [1] - Among the index constituents, 22 stocks rose while 27 fell, with Hualan Vaccine leading the gainers at 2.57% and Jingxin Pharmaceutical leading the decliners at 5.97% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (12.58% weight, latest price 196.30 yuan, market cap 238 billion yuan) [1] - Changchun High-tech (4.87% weight, latest price 99.66 yuan, market cap 40.655 billion yuan) [1] - Shimi Aoshi (4.74% weight, latest price 6.60 yuan, market cap 4.3811 billion yuan) [1] - Kanglong Chemical (4.55% weight, latest price 28.87 yuan, market cap 51.337 billion yuan) [1] - Tigermed (4.54% weight, latest price 51.20 yuan, market cap 44.085 billion yuan) [1] - Deep Technology (4.16% weight, latest price 23.42 yuan, market cap 36.809 billion yuan) [1] - Muyuan Food (3.62% weight, latest price 49.90 yuan, market cap 272.592 billion yuan) [1] - Lepu Medical (3.19% weight, latest price 15.87 yuan, market cap 29.255 billion yuan) [1] - Aimeike (3.16% weight, latest price 146.26 yuan, market cap 44.257 billion yuan) [1] - Seeyou Medical (3.07% weight, latest price 35.70 yuan, market cap 35.788 billion yuan) [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 84.2481 million yuan from institutional investors, while retail investors saw a net inflow of 67.1618 million yuan [1] - Notable capital flows include: - Muyuan Food: 104 million yuan net inflow from institutional investors, but net outflows from retail and speculative investors [2] - Aimeike: 46.9918 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2] - Mindray Medical: 33.0761 million yuan net inflow from institutional investors, with outflows from retail and speculative investors [2]

| 建筑材料 | | | | 国统股份 | | | --- | --- | --- | --- | --- | --- | | 传媒 | -0.39 | 436.88 | -24.40 | 欢瑞世纪 | -9.95 | | 商贸零售 | -0.46 | 180.58 | 22.34 | 凯淳股份 | -11.20 | | 综合 | -0.96 | 35.25 | 5.30 | 三木集团 | -4.36 | 证券时报·数据宝统计，截至上午收盘，今日沪指涨0.49%，A股成交量684.66亿股，成交金额10970.18 亿元，比上一个交易日减少4.06%。个股方面，3338只个股上涨，其中涨停53只，1884只个股下跌，其 中跌停9只。从申万行业来看，电子、美容护理、轻工制造等涨幅最大，涨幅分别为1.75%、1.26%、 1.00%；综合、商贸零售、传媒等跌幅最大，跌幅分别为0.96%、0.46%、0.39%。（数据宝） （文章来源：证券时报网） 今日各行业表现（截至上午收盘） | 申万行业 | 行业涨跌（%） | 成交额（亿元） | 比上日（%） | 领涨（跌）股 | 涨跌幅（%） | | --- | --- ...

Timing Outlook - The overall A-share market is expected to continue a slow bull recovery in 2026 from a macro perspective of credit inflation, observing valuation, risk premium, and sentiment from a micro perspective [3][42] - The current risk premium is in a balanced area, with the ChiNext index's style valuation at a relative historical median level [42] - The proportion of stocks above the 200-day moving average reflects market heat, currently in a balanced area [42] - The latest thematic allocation focuses on energy and high-dividend sectors using convolutional neural networks to model price and volume data [3][39] Style and Industry Allocation Outlook - The macroeconomic environment is expected to improve, with small-cap growth styles performing significantly better, particularly in sectors like social services, beauty care, power equipment, pharmaceutical biology, and electronics [4][12] - Industries with relatively low valuations and high expected earnings growth for 2026 include agriculture, social services, home appliances, food and beverage, automotive, and non-ferrous metals [4][50] - The inflow of northbound funds is concentrated in sectors such as electronics, power equipment, non-ferrous metals, machinery, and communications [4][55] - The best allocation period for small-cap growth is February, with a focus on technology in February and May, and consumer sectors in April and year-end [4][61] 2025 Market Review - The A-share market showed strong performance in 2025, with the ChiNext index rising by 36.4% year-to-date as of November 21 [7] - The small-cap growth style, represented by the CSI 1000 and small-cap growth indices, performed well, with increases of 6.7% and 4.5% respectively in the first half of the year [12] - The non-ferrous metals sector led the industry gains, with an increase of 65.7% year-to-date [15] 2026 Macro Environment Outlook - The macroeconomic environment is expected to improve, with inflation trends likely to rise, particularly as PPI shows signs of recovery after three years of low fluctuations [44][47] - Historical PPI recovery phases indicate that small-cap and growth sectors tend to outperform during these periods [47] Valuation and Earnings Expectations - The current valuation levels indicate that the ChiNext index and other indices still have cost-effectiveness for allocation, particularly in consumption and cyclical sectors [50][52] - Key industries to focus on for long-term investment opportunities include agriculture, social services, home appliances, food and beverage, automotive, and non-ferrous metals, based on relative valuation and expected earnings growth for 2026 [50][54]

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4375.4 points on November 25, with a 0.52% increase and a trading volume of 8.459 billion HKD, indicating a positive market sentiment in the healthcare sector [1]. Group 1: Index Performance - The index had 40 stocks rising and 16 stocks falling on the day, with Ping An Good Doctor leading the gainers at a 4.27% increase, while Ruimaite led the decliners with a 1.98% drop [1]. - The index's turnover rate was 0.84%, reflecting moderate trading activity [1]. Group 2: Component Stocks Details - The top ten component stocks of the index include: - Mindray Medical (14.56% weight, 193.88 HKD, 0.46% increase, market cap 235.068 billion HKD) [1] - Yeye Eye Hospital (11.62% weight, 11.59 HKD, 0.35% increase, market cap 108.081 billion HKD) [1] - Lejin Medical (4.85% weight, 15.80 HKD, 0.45% increase, market cap 29.126 billion HKD) [1] - Aimeike (4.80% weight, 145.54 HKD, -0.31% decrease, market cap 44.039 billion HKD) [1] - Yuyue Medical (4.66% weight, 35.67 HKD, -0.14% decrease, market cap 35.758 billion HKD) [1] - Yingke Medical (3.64% weight, 40.26 HKD, 0.20% increase, market cap 26.362 billion HKD) [1] - Furuishi (3.59% weight, 65.75 HKD, -1.50% decrease, market cap 17.422 billion HKD) [1] - Meinian Health (3.58% weight, 5.42 HKD, 0.74% increase, market cap 21.215 billion HKD) [1] - Sinopharm (3.35% weight, 18.55 HKD, 0.49% increase, market cap 57.888 billion HKD) [1] - Ping An Good Doctor (2.63% weight, 13.33 HKD, 4.27% increase, market cap 28.822 billion HKD) [1]. Group 3: Capital Flow - The net outflow of main funds from the index's component stocks totaled 251 million HKD, while retail investors saw a net inflow of 199 million HKD [1]. - The detailed capital flow indicates that while main funds were withdrawing, retail investors were actively buying into the market [2]. Group 4: Recent Adjustments - In the last 10 days, the index underwent adjustments, adding one new stock, Jianfa Zhixin, which is in the medical biology sector with a market cap of 13.886 billion HKD [3].

Core Viewpoint - The Biotech Index (970038) closed at 2135.75 points on November 25, with a gain of 0.48% and a trading volume of 15.716 billion yuan, indicating a positive market sentiment in the biotech sector [1]. Group 1: Index Performance - The Biotech Index had 35 stocks rising and 14 stocks falling on the reporting day, with Hualan Vaccine leading the gainers at an increase of 11.25%, while Palin Bio led the decliners with a drop of 1.69% [1]. - The turnover rate for the Biotech Index was 1.21%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (12.58% weight) at 193.88 yuan, up 0.46%, with a market cap of 235.068 billion yuan [1]. - Changchun High-tech (4.87% weight) at 99.46 yuan, up 0.10%, with a market cap of 40.573 billion yuan [1]. - Other notable constituents include Kanglong Chemical, Tigermed, and Muyuans, all within the biotech and related sectors [1]. Group 3: Capital Flow - The net outflow of main funds from the Biotech Index constituents totaled 36.3674 million yuan, while retail investors experienced a net outflow of 27.1 million yuan [1]. - Conversely, there was a net inflow of 307 million yuan from speculative funds, indicating a mixed sentiment among different investor types [1].

Core Viewpoints - The market is currently experiencing a short-term adjustment, with low market sentiment. However, the downward space for the index is considered limited, and the year-end adjustment presents a good opportunity for positioning for the coming year, particularly focusing on mid-cap blue chips [4][15]. Market Outlook - The short-term market adjustment does not alter the ongoing oscillating trend. The adjustment is influenced by both internal and external factors. Externally, there is a downward revision of the expectation for a decline in overseas risk-free interest rates in December. Internally, the risk appetite of high-risk investors is declining faster than that of low-risk investors. It is anticipated that the external factors may ease, and the risk appetite will gradually converge towards the middle. Overall, the future outlook remains stable with a mix of gains and losses, maintaining a sideways oscillation with a slight upward trend [5][16]. Industry Comparison - The layout for mid-cap blue chips is timely. Since March 2023, the market has seen a consensus expectation for a rally in both technology and dividend stocks. The report suggests that the trend of risk styles at both ends is nearing its end, and future investment opportunities lie in stocks with medium risk characteristics. The long-dormant mid-cap blue chip market is expected to rise again, making the current market adjustment a favorable time for positioning [6][17]. Industry Allocation - Investment opportunities are identified in medium-risk stocks, focusing on three main lines: 1. The manufacturing sector is shifting from "dream narratives" to "reality verification," emphasizing the need for investments based on orders and revenue verification, particularly in communications, electronics, power equipment, and machinery [7][18]. 2. The consumer sector, which has been quiet for years, is approaching a turning point. Many consumer stocks are undervalued, and with supply contraction, prices are expected to rise. Key areas of focus include the restaurant supply chain, second and third-tier liquor, snacks and beverages, hotels, human resources, and beauty care [7][18]. 3. The cyclical sector is undergoing a revaluation driven by technological empowerment and supply constraints. Attention should be given to new materials and strategic minor metals (such as antimony and rare earths), as well as industrial metals (copper and aluminum) that are experiencing improved supply-demand dynamics, along with traditional commodities like live pigs and rubber [7][18]. Thematic Investments - The report highlights several thematic investment areas: - The Google & Alibaba supply chain, where there is significant divergence in market expectations regarding AI development. The next phase may present opportunities across the entire supply chain from applications to large models and upstream computing power [8][19]. - Semiconductor expansion and domestic substitution, with expectations for domestic wafer fabs to expand production next year and the capital progress of domestic storage chip leaders. The development of domestic semiconductor materials is expected to accelerate amid international relations challenges [8][19]. - Solid-state batteries, where the market is closely monitoring industrial progress. The acceleration point for solid-state battery industrialization has emerged, with the order-driven phase beginning in the equipment/materials segment [8][19]. - Aerospace satellites, which are entering a development opportunity period with expected catalysts. The IPO progress of industry leaders is anticipated to accelerate, with various fields such as constellation networking and satellite bidding expected to see rapid implementation [8][20]. - Upstream price increases, driven by supply contraction and structural demand growth, are expected to provide price elasticity for related products, particularly in the upstream of the new energy industry, chemicals, and non-ferrous metals [8][20].

盘后数据出炉。 今日（11月21日），A股单边下挫，市场逾5000股下跌，截至收盘，上证指数跌2.45%，深证成指跌3.41%，创业板指跌4.02%，A股全天成交1.98万亿元，上日成交 1.72万亿元。 1.两市主力资金净流出超980亿元 今日沪深两市主力资金开盘净流出392.77亿元，尾盘净流出143.68亿元，两市全天主力资金净流出985.55亿元。 | | | 沪深两市最近五个交易日主力资金流向情况 (亿元) | | | | --- | --- | --- | --- | --- | | 日期 | 净流入金额 | 开盘净流入 | 尾盘净流入 | 超大单净买入 | | 2025-11-21 | -985.55 | -392.77 | -143.68 | -521.53 | | 2025-11-20 | -366.03 | -48.79 | -67.73 | -155.72 | | 2025-11-19 | -348.42 | -123.87 | 5.59 | -178.90 | | 2025-11-18 | -624.24 | -232.22 | -66.11 | -354.10 | | 2025-11 ...

Core Viewpoint - The Biotech Index (970038) experienced a decline of 2.26% on November 21, closing at 2111.48 points, with a total trading volume of 19.114 billion yuan and a turnover rate of 1.64% [1] Group 1: Index Performance - On the day, only one constituent stock, Prolo Pharmaceutical, saw an increase of 1.41%, while 49 stocks declined, with Iwu Biological leading the drop at 5.0% [1] - The top ten constituent stocks of the Biotech Index are primarily in the biopharmaceutical sector, with significant weightings for companies like Mindray Medical (12.58%) and Changchun High-tech (4.87%) [1] Group 2: Market Capitalization and Price Movements - The total market capitalization of the top ten stocks ranges from 2365.59 billion yuan for Mindray Medical to 285.91 billion yuan for Lepu Medical, indicating a diverse range of company sizes within the index [1] - Price movements for the top stocks include declines for major players such as Mindray Medical (-1.88%) and Changchun High-tech (-2.73%) [1] Group 3: Capital Flow - The Biotech Index constituents saw a net outflow of 1.929 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.724 billion yuan [3] - Notable capital flows include Peak High-Tech with a net inflow of 22.415 million yuan from institutional investors, while other stocks like Jiayuan Pharmaceutical experienced significant outflows [3]

Report Summary 1. Investment Rating - No investment rating for the industry is provided in the report. 2. Core Viewpoints - The central bank carried out 300 billion yuan of 7 - day reverse repurchase operations, with a net investment of 110 billion yuan on the day. The 11 - month LPR quote remained unchanged, and the central bank will implement a moderately loose monetary policy [3][4]. - The market sentiment was cautious, with the stock index oscillating and closing down. The macro - level is a mix of positives and negatives. The market lacks a core driving force, and there are differences in market expectations. The stock index is expected to continue the oscillating pattern with support at the bottom and pressure upwards [6]. 3. Key Points by Category Monetary Policy and Interest Rates - The central bank conducted 300 billion yuan of 7 - day reverse repurchase operations at an operating rate of 1.40%, with a net investment of 110 billion yuan after 190 billion yuan of reverse repurchases matured [3]. - The 11 - month LPR remained unchanged, with the 1 - year LPR at 3.0% and the 5 - year LPR at 3.5%. The central bank will implement a moderately loose monetary policy [4]. - Interest rates of various varieties changed, such as DRO01 at 1.37% (- 5.67bp), DR007 at 1.49% (- 2.74bp), etc. [3] Stock Index and Market Conditions - The stock indexes fell, with the Shanghai - Shenzhen 300 down 0.51% to 4564.9, the Shanghai 50 down 0.4% to 3008.3, the CSI 500 down 0.85% to 7061.9, and the CSI 1000 down 0.63% to 7340.4. The trading volume of the two markets was 1.7082 trillion yuan, a decrease of 17.7 billion yuan [6]. - The market sentiment was cautious, and the stock index oscillated and closed down. The market lacks a core driving force, and there are differences in market expectations. The stock index is expected to continue the oscillating pattern [6]. Futures Market - Futures prices of different varieties changed, such as IF down 0.6%, IH down 0.3%, IC down 0.7%, and IM down 0.6%. Trading volumes and open interests also had different changes [5]. - The premium and discount rates of different futures contracts varied, for example, IF's premium rate for the current - month contract was 55.56%, and IH's discount rate for the current - month contract was - 3.76% [7].